Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by DAFNA Capital Management LLC

DAFNA Capital Management LLC increased its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 76.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 130,316 shares of the company’s stock after buying an additional 56,562 shares during the quarter. DAFNA Capital Management LLC owned about 0.32% of Keros Therapeutics worth $2,063,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MetLife Investment Management LLC increased its position in Keros Therapeutics by 6.0% during the fourth quarter. MetLife Investment Management LLC now owns 18,098 shares of the company’s stock worth $286,000 after purchasing an additional 1,027 shares during the last quarter. Handelsbanken Fonder AB grew its position in Keros Therapeutics by 11.3% during the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock valued at $171,000 after acquiring an additional 1,100 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Keros Therapeutics by 19.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after purchasing an additional 1,372 shares during the period. Virtus ETF Advisers LLC raised its holdings in Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock valued at $61,000 after buying an additional 1,998 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Keros Therapeutics by 2.6% in the 4th quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company’s stock valued at $1,549,000 after acquiring an additional 2,462 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Piper Sandler decreased their target price on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, January 17th. Wedbush reaffirmed a “neutral” rating and issued a $15.00 price target on shares of Keros Therapeutics in a report on Tuesday, April 1st. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Truist Financial reduced their price target on shares of Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, April 9th. Finally, Oppenheimer decreased their target price on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday, January 16th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Keros Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now directly owns 4,392,737 shares of the company’s stock, valued at $44,498,425.81. The trade was a 27.01 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 22.90% of the stock is currently owned by company insiders.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $13.68 on Thursday. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37. The stock has a market capitalization of $555.64 million, a P/E ratio of -2.63 and a beta of 1.32. The business’s fifty day moving average is $12.10 and its two-hundred day moving average is $25.34.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping the consensus estimate of ($0.01) by $3.63. The business had revenue of $211.25 million during the quarter, compared to analysts’ expectations of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same period last year, the company posted ($1.21) earnings per share. On average, research analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.